IP Verse

Methods Of Treating Bacterial Infections - EP3285776

The patent EP3285776 was granted to Melinta Therapeutics on Dec 21, 2022. The application was originally filed on Apr 20, 2016 under application number EP16783764A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3285776

MELINTA THERAPEUTICS
Application Number
EP16783764A
Filing Date
Apr 20, 2016
Status
Granted And Under Opposition
Nov 18, 2022
Publication Date
Dec 21, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKSep 21, 2023ELKINGTON AND FIFEADMISSIBLE

Patent Citations (4) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS8680136
DESCRIPTIONWO8705297
INTERNATIONAL-SEARCH-REPORTWO2013184845
OPPOSITIONWO2013184845

Non-Patent Literature (NPL) Citations (25) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- BOU, G. et al., J. Antimicrob. Agents Chemother., (20000000), vol. 44, page 1556
DESCRIPTION- BOU, G.MARTINEZ-BELTRAN, J., Antimicrob. Agents Chemother., (20000000), vol. 50, page 2280
DESCRIPTION- KUTI J L et al., J. of Critical Care, (20100000), vol. 25, pages 155 - 156
DESCRIPTION- KUTI J. L. et al., "Use of Monte Carlo simulation to design an optimized pharmacodynamics dosing strategy for meropenem", J Clin Pharmacol., (20030000), vol. 43, no. 10, pages 1116 - 23
DESCRIPTION- LODISE T.P. et al., "Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia", Antimicrob Agents Chemother., (20110000), vol. 55, no. 4, pages 1606 - 10
DESCRIPTION- MONTEFOUR, K. et al., Crit. Care Nurse, (20080000), vol. 28, page 15
DESCRIPTION- PEREZ, F. et al., Expert Rev. Anti Infect. Ther., (20080000), vol. 6, page 269
DESCRIPTION- POWELL et al., "Compendium of Excipients for Parenteral Formulations", PDA J Pharm Sci and Tech, (19980000), vol. 52, pages 238 - 311, XP009119027
DESCRIPTION- YAGI YUSUKE et al., J. Clin. Pharm., (20140000), vol. 36, pages 648 - 656
DESCRIPTION- NEMA et al., "Excipients and Their Role in Approved Injectable Products: Current Usage and Future Directions", PDA J Pharm Sci and Tech, (20110000), vol. 65, doi:10.5731/pdajpst.2011.00634, pages 287 - 332, XP009166667
INTERNATIONAL-SEARCH-REPORT- "A Phase 3, Multi-Center, Randomized, Open-Label Study of Carbavance (Meropenem/RPX7009) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae", Clinical Trial NCT02168946, (20141006), URL: https://clinicaltrials.gov/archive/NCT02168946/2014_10_06, (20160520), XP 055325228 [X] 1-59 * See "Detailed description" and the section entitled "Arm/Group" *
INTERNATIONAL-SEARCH-REPORT- HECKER, S.J. et al., "Discovery of a Cyclic Boronic Acid beta-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases", Journal of Medicinal Chemistry, (20150000), vol. 58, no. 9, pages 3682 - 3692, XP 055325230 [X] 1-59 * See page 3690, the paragraph entitled "Mouse Efficacy Studies"; page 3687, the paragraph entitled "Efficacy"; Figure 7 *
INTERNATIONAL-SEARCH-REPORT- LAPUEBLA, A. et al., "Activity of Meropenem Combined with RPX7009, a Novel beta- Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City", Antimicrobial Agents and Chemotherapy, (20150800), vol. 59, no. 8, pages 4856 - 4860, XP 055325282 [PX] 1-59 * See the abstract *
INTERNATIONAL-SEARCH-REPORT- SABET, M. et al., "In Vivo Efficacy of Carbavance (meropenem/RPX7009) against KPC-producing Enterobacteriaceae", Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy, (20140000), vol. 54, page F-958, XP009506892 [X] 1-59 * See the entire abstract *
OPPOSITION- D GRIFFITH D et al., "Abstract: A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor RPX7009 Alone, Meropenem Alone, and both in Combination (Carbavance) TID for 7 days in Healthy Adult Subjects (IDWeek 2014", 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), (20140900), XP055534351
OPPOSITION- Green Alan, "Dialysis: management", Pharmaceutical Journal, (20150320), pages 1 - 7, XP093087269
OPPOSITION- M. DOOGUE et al., "Drug Dosing in Renal Disease", Clin Biochem, (20110500), vol. 32, XP055613691
OPPOSITION- MUNAR et al., "Drug Dosing Adjustments in Patients with Chronic Kidney Disease", Am. Fam. Physician., (20070000), vol. 75, page 1497, XP055410272
OPPOSITION- YAGI YUSEKE et al., "Outcome evaluation of an intervention to improve the effective and safe use of meropenem", INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, DORDRECHT, (20140420), vol. 36, no. 3, doi:10.1007/s11096-014-9949-2, ISSN 2210-7703, pages 648 - 656, XP035315830
OPPOSITION- R.DRAENERT et al., Novel Antibiotics: Are we still in the pre-post-antibiotic era?, (20150000), vol. 43, pages 145 - 151, XP035445153
OPPOSITION- KUTI J L et al., "Optimal cefepime and meropenem dosing for ventilator-associated pneumonia patients with reduced renal function: An update to our clinical pathway", Journal of Critical Case, Grune and Stratton, vol. 25, no. 1, doi:10.1016/j.jcrc.2010.01.001, pages 155 - 156, XP026923027
OPPOSITION- HECKER, S.J. et al., "Discovery of a Cyclic Boronic Acid beta-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases", Journal of Medicinal Chemistry, vol. 58, no. 9, doi:10.1021/acs.jmedchem.5b00127, pages 3682 - 3692, XP055325230
SEARCH- D Griffith D ET AL, "Abstract: A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the Beta-lactamase inhibitor RPX7009 Alone, Meropenem Alone, and both in Combination (Carbavance) TID for 7 days in Healthy Adult Subjects (IDWeek 2014)", 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Washington, DC, USA; September 05 -09, 2014, (20141009), pages F - 560, URL: https://idsa.confex.com/idsa/2014/webprogram/Paper48056.html, (20181214), XP055534351 [Y] 1-16 * the whole document *
SEARCH- YAGI YUSUKE ET AL, "Outcome evaluation of an intervention to improve the effective and safe use of meropenem", INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, SPRINGER NETHERLANDS, DORDRECHT, vol. 36, no. 3, doi:10.1007/S11096-014-9949-2, ISSN 2210-7703, (20140420), pages 648 - 656, (20140420), XP035315830 [Y] 1-16 * abstract *
SEARCH- KUTI J L ET AL, "Optimal cefepime and meropenem dosing for ventilator-associated pneumonia patients with reduced renal function: An update to our clinical pathway", JOURNAL OF CRITICAL CARE, GRUNE AND STRATTON, ORLANDO, FL, US, vol. 25, no. 1, doi:10.1016/J.JCRC.2010.01.001, ISSN 0883-9441, (20100301), pages 155 - 156, (20100225), XP026923027 [Y] 1-16 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents